Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ:ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 

Enlivex Therapeutics is a clinical stage, macrophage reprogramming immunotherapy company developing Allocetra - an off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.

Watch full interview here

Feature photo 


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechPenny StocksHealth CareGeneralBenzinga All AccessEnlivex Therapeutics